WO2000050088A3 - Biotinylated-chemokine antibody complexes - Google Patents

Biotinylated-chemokine antibody complexes Download PDF

Info

Publication number
WO2000050088A3
WO2000050088A3 PCT/US2000/004312 US0004312W WO0050088A3 WO 2000050088 A3 WO2000050088 A3 WO 2000050088A3 US 0004312 W US0004312 W US 0004312W WO 0050088 A3 WO0050088 A3 WO 0050088A3
Authority
WO
WIPO (PCT)
Prior art keywords
biotinylated
complexes
biotin
antibody complexes
chemokine antibody
Prior art date
Application number
PCT/US2000/004312
Other languages
French (fr)
Other versions
WO2000050088A2 (en
Inventor
Walter Newman
Dominic Picarella
Dulce Soler
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Priority to MXPA01008465A priority Critical patent/MXPA01008465A/en
Priority to CA002371849A priority patent/CA2371849A1/en
Priority to JP2000600698A priority patent/JP2002537362A/en
Priority to EP00911877A priority patent/EP1154799A2/en
Priority to AU33700/00A priority patent/AU3370000A/en
Publication of WO2000050088A2 publication Critical patent/WO2000050088A2/en
Publication of WO2000050088A3 publication Critical patent/WO2000050088A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Biotinylated pharmacologically active agents and complexes containing same are disclosed. In particular, biotinylated-chemokines are described. The complexes further include an anti-biotin antibody that selectively binds to biotin. The complex can be dissociated by contact with free biotin. The complexes are particularly useful for enhancing an immune response to tumor cells and virus-infected cells, in vivo or in vitro.
PCT/US2000/004312 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes WO2000050088A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA01008465A MXPA01008465A (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes.
CA002371849A CA2371849A1 (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes
JP2000600698A JP2002537362A (en) 1999-02-22 2000-02-18 Biotinylated chemokine antibody conjugate
EP00911877A EP1154799A2 (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes
AU33700/00A AU3370000A (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12100699P 1999-02-22 1999-02-22
US60/121,006 1999-02-22

Publications (2)

Publication Number Publication Date
WO2000050088A2 WO2000050088A2 (en) 2000-08-31
WO2000050088A3 true WO2000050088A3 (en) 2000-12-21

Family

ID=22393879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004312 WO2000050088A2 (en) 1999-02-22 2000-02-18 Biotinylated-chemokine antibody complexes

Country Status (6)

Country Link
EP (1) EP1154799A2 (en)
JP (1) JP2002537362A (en)
AU (1) AU3370000A (en)
CA (1) CA2371849A1 (en)
MX (1) MXPA01008465A (en)
WO (1) WO2000050088A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331568B1 (en) 2008-09-10 2014-09-03 ITH Immune Therapy Holdings AB Treating inflammatory conditions
BR112013014644A2 (en) * 2011-01-03 2017-03-07 F Hoffmann - La Roche Ag pharmaceutical composition and complex
WO2012172339A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory arthritis
ES2760300T3 (en) 2011-06-13 2020-05-13 Tla Targeted Immunotherapies Ab Diagnosis and treatment of inflammatory bowel disease and irritable bowel syndrome
WO2012172345A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with allergy
WO2012172344A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with sepsis
WO2012172336A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
WO2012172340A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating mental disorders
DK2717940T3 (en) 2011-06-13 2020-07-13 Tla Targeted Immunotherapies Ab Treatment of conditions associated with metabolic syndrome
DK3228631T3 (en) 2011-06-13 2020-09-28 Tla Targeted Immunotherapies Ab TREATMENT OF RESPIRATORY CONDITIONS
ES2664836T3 (en) 2011-06-13 2018-04-23 Tla Targeted Immunotherapies Ab Multiple sclerosis treatment
WO2012172337A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
EP2717941B1 (en) 2011-06-13 2020-04-01 TLA Targeted Immunotherapies AB Treating cancer
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
WO2012172343A2 (en) 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
JP6247287B2 (en) * 2012-07-04 2017-12-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Anti-biotin antibodies and methods of use
AU2013285422B2 (en) 2012-07-04 2017-04-27 F. Hoffmann-La Roche Ag Covalently linked antigen-antibody conjugates
PL2869837T3 (en) 2012-07-04 2017-03-31 F.Hoffmann-La Roche Ag Anti-theophylline antibodies and methods of use
KR102051433B1 (en) * 2013-08-27 2020-01-08 (주)네오팜 A composition and external application for acceleration of muscle differentiation and improving of muscle mass
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (en) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugate, pharmaceutical formulation and use
MX2016015280A (en) 2014-06-26 2017-03-03 Hoffmann La Roche Anti-brdu antibodies and methods of use.
CN110088129A (en) * 2016-12-27 2019-08-02 豪夫迈·罗氏有限公司 New biotin monoclonal antibody specific and application thereof
JP6901562B2 (en) 2016-12-27 2021-07-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ New biotin-specific monoclonal antibody and its use
WO2018122205A2 (en) 2016-12-27 2018-07-05 F. Hoffmann-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
CN111171154B (en) 2020-02-25 2021-05-11 杭州百凌生物科技有限公司 Anti-biotin antibody and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460569A1 (en) * 1990-06-04 1991-12-11 Tecnogen S.C.P.A. Process for identifying polynucleotide sequences and device suitable therefor
WO1996040251A1 (en) * 1995-06-07 1996-12-19 Ophidian Pharmaceuticals, Inc. Prevention and treatment of sepsis
WO1998033914A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
WO2000012554A1 (en) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Method for marked chemokine synthesis, marked chemokine and analysis kit
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460569A1 (en) * 1990-06-04 1991-12-11 Tecnogen S.C.P.A. Process for identifying polynucleotide sequences and device suitable therefor
WO1996040251A1 (en) * 1995-06-07 1996-12-19 Ophidian Pharmaceuticals, Inc. Prevention and treatment of sepsis
WO1998033914A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
WO2000012554A1 (en) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Method for marked chemokine synthesis, marked chemokine and analysis kit
WO2000042071A2 (en) * 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BATRA, RAJ K. ET AL: "Receptor-mediated gene delivery employing lectin-binding specificity", XP002149353, retrieved from STN Database accession no. 121:271451 *
GENE THER. (1994), 1(4), 255-60 *

Also Published As

Publication number Publication date
CA2371849A1 (en) 2000-08-31
EP1154799A2 (en) 2001-11-21
WO2000050088A2 (en) 2000-08-31
JP2002537362A (en) 2002-11-05
MXPA01008465A (en) 2003-06-06
AU3370000A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
WO2000050088A3 (en) Biotinylated-chemokine antibody complexes
HK1033582A1 (en) Antibodies to death receptor 4 (dr4) and uses thereof
CA2333732A1 (en) Redox reversible imidazole-osmium complex conjugates
CA2359440A1 (en) Phenylphenanthridines with pde-iv inhibiting activity
MY109880A (en) Substituted biphenylpyridones
EP2213302A3 (en) DR4 antibodies and uses thereof
HK1045763A1 (en) Fuel assembly and method for use with the fuel cell assembly.
CA2298018A1 (en) Methods and compositions for inhibiting angiogenesis
EP1985632A3 (en) Use of VEGF2 antibodies for inhibiting photoreceptor cell proliferation
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
IT1307234B1 (en) FERMENTATION TANK, PARTICULARLY FOR THE RED VINIFICATION.
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU3365499A (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
DE69920949D1 (en) ASCOMYCIN-CONTAINING TOPICAL PREPARATIONS
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2000066731A3 (en) Recombinant laminin 5
ATE265336T1 (en) CARRIER
MX9708697A (en) Method of diagnosing prostate cancer.
AU3012599A (en) Methods, kits and compositions pertaining to detection complexes
WO2001000799A8 (en) Novel protein and dna thereof
AU1197001A (en) B cell clonal toxins and methods for using the same
WO2000048622A3 (en) Method for inhibiting inflammatory responses
CA2360311A1 (en) Improved dialysis solutions and methods
AU1198501A (en) Magnetically modified fuel cells
WO2001048182A3 (en) Amino acid inducible expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000911877

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 33700/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 600698

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2371849

Country of ref document: CA

Ref country code: CA

Ref document number: 2371849

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/008465

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2000911877

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000911877

Country of ref document: EP